PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
7076794-6	1982	The addition of levonorgestrel (250 micrograms/day, orally) to the treatment reversed both effects of estrogen, so that HDL2 cholesterol and phospholipid levels fell below and hepatic lipase activity rose above the respective pretreatment values.	Levonorgestrel	16-30	junctophilin 3	Homo sapiens	120-124	
3158321-5	1985	Levonorgestrel reduced the HDL and particularly the HDL2 cholesterol concentrations (mean change from 1.75 to 1.45 mmol/l for HDL and from 0.73 to 0.50 mmol/l for HDL2, P less than 0.001).	Levonorgestrel	0-14	junctophilin 3	Homo sapiens	52-56	
3158321-5	1985	Levonorgestrel reduced the HDL and particularly the HDL2 cholesterol concentrations (mean change from 1.75 to 1.45 mmol/l for HDL and from 0.73 to 0.50 mmol/l for HDL2, P less than 0.001).	Levonorgestrel	0-14	junctophilin 3	Homo sapiens	163-167	
6801982-4	1982	The levonorgestrel-containing pills and the progestin-only OC significantly depressed HDL2 cholesterol levels and the ratio of HDL2 to LDL cholesterol.	Levonorgestrel	4-18	junctophilin 3	Homo sapiens	86-90	
6801982-4	1982	The levonorgestrel-containing pills and the progestin-only OC significantly depressed HDL2 cholesterol levels and the ratio of HDL2 to LDL cholesterol.	Levonorgestrel	4-18	junctophilin 3	Homo sapiens	127-131	
6460509-2	1981	Levonorgestrel, a nortestosterone-derived steroid with androgenic activity reduced plasma HDL cholesterol by 17% (P less than 0.05) and HDL2 cholesterol by 30% (P less than 0.05), without changing the HDL3 cholesterol concentration.	Levonorgestrel	0-14	junctophilin 3	Homo sapiens	136-140